Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Dose Optimization in Renal Cell Carcinoma
NCT03173560Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of lenvatinib in renal cell carcinoma (RCC), sponsored by Eisai Co., Ltd.. Started Aug 2017; status: completed.
02
Drugs
lenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03173560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173560.